BNP-guided therapy optimizes the timing of discharge and the medium term risk stratification in patients admitted for congestive heart failure
most important cause of hospitalizations and is associated with high cost. Despite a consistent body of data demonstrating the benefits of drug therapy in HF, persistently high rates of readmission, especially within six months of discharge, continue to be documented. Neurohormonal activation charac...
Main Authors: | Roberto Valle, Nadia Aspromonte, Emanuele Carbonieri, Giorgio De Michele, Giuseppe Di Tano, Prospero Giovinazzo, Roberta Cioè, Tiziana Di Giacomo, Loredano Milani, Federica Noventa, Mario Chiatto |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2016-02-01
|
Series: | Monaldi Archives for Chest Disease |
Subjects: | |
Online Access: | https://www.monaldi-archives.org/index.php/macd/article/view/448 |
Similar Items
-
The integration of BNP and NT-proBNP into clinical medicine
by: Swiss Medical Weekly
Published: (2007-01-01) -
B-type natriuretic peptide (BNP): can it improve our management of patients with congestive heart failure?
by: Swiss Medical Weekly
Published: (2002-11-01) -
Correlation of NT-proBNP levels with clinical and echocardiographic features in evaluation of patients admitted with heart failure
by: Dhinakaran K, et al.
Published: (2023-12-01) -
Stay Home! Stay Safe! First Post-Discharge Cardiologic Evaluation of Low-Risk–Low-BNP Heart Failure Patients in COVID-19 Era
by: Nadia Aspromonte, et al.
Published: (2021-05-01) -
Serum brain natriuretic peptide (BNP) and N-terminal brain natriuretic peptide (NT-proBNP) in heart valve disease
by: J.A. Moolman, et al.
Published: (2017-04-01)